Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$251 Mln
Revenue (TTM)
$134 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1
Industry P/E
--
EV/EBITDA
-7.7
Div. Yield
0 %
Debt to Equity
0
Book Value
$6.7
EPS
$-0.9
Face value
--
Shares outstanding
41,266,335
CFO
$-223.21 Mln
EBITDA
$-231.58 Mln
Net Profit
$-10.26 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Rxsight Inc (RXST)
| -39.2 | -15.2 | -39.2 | -74.9 | -27.6 | -- | -- |
|
BSE Sensex*
| -13.8 | -10.2 | -14.3 | -4.0 | 7.3 | 7.8 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Rxsight Inc (RXST)
| -69.7 | -14.6 | 218.2 | 12.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Rxsight Inc (RXST)
|
6.3 | 251.3 | 134.5 | -38.9 | -28.9 | -14 | -- | 1.0 |
| 7.8 | 5,176.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 36.1 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 25.9 | 3,989.0 | 2,719.5 | 47.0 | 8.4 | 1.6 | 86.6 | 1.3 | |
| 112.6 | 6,098.9 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 8.9 | |
| 75.7 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.0 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 329.0 | 12,879.6 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.5 | 9.2 | |
| 118.3 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,409.8 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.1 | 2.6 |
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that... enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California. Address: 100 Columbia, Aliso Viejo, CA, United States, 92656 Read more
President, CEO & Director
Dr. Ronald M. Kurtz M.D.
President, CEO & Director
Dr. Ronald M. Kurtz M.D.
Headquarters
Aliso Viejo, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Rxsight Inc (RXST) is $6.34 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Rxsight Inc (RXST) has given a return of -27.56% in the last 3 years.
Since, TTM earnings of Rxsight Inc (RXST) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-10.97
|
1.55
|
|
2024
|
-48.84
|
4.77
|
|
2023
|
-28.20
|
8.55
|
|
2022
|
-5.31
|
3.95
|
|
2021
|
-3.23
|
1.14
|
The 52-week high and low of Rxsight Inc (RXST) are Rs 26.38 and Rs 5.90 as of 02-Apr-2026.
Rxsight Inc (RXST) has a market capitalisation of $ 251 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Rxsight Inc (RXST), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.18
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.